This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- Liraglutide (Saxenda) added to lifestyle intervention helped reduce BMI in young children with obesity, the phase IIIa SCALE Kids trial found. By week 56, kids, ages 6 to <12 years, on once-daily 3-mg liraglutide lost 5.8.
Higher body mass index (BMI) variability is associated with adverse cardiovascular disease (CVD) events, according to a study published online March 21 in JAMA Network Open.
Genetic instruments for MI, smoking initiation, alcohol consumption, and BMI were derived from large-scale genome-wide association studies. Smoking initiation and BMI were identified as potential mediators. ConclusionsThe results of this MR analysis demonstrate that insomnia increases the risk of MI.
Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.
What is the efficacy and safety of non–vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW)?
(MedPage Today) -- Tirzepatide (Zepbound) was effective at reducing body weight in Chinese adults with lower cutoffs for overweight or obesity, the SURMOUNT-CN trial reported. In the study of 210 adults without diabetes, participants on tirzepatide.
Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.
These results highlight the potential of preventing increasing CKD burden and of preventing subsequent cardiovascular conditions, especially given current rates of obesity among adolescents.
BackgroundIndividuals diagnosed with type 2 diabetes mellitus (T2DM) commonly exhibit elevated lipid levels and an increased body mass index (BMI). The impact of BMI on the efficacy of statins in reducing lipid levels among diabetic patients remains uncertain.
(MedPage Today) -- A higher body mass index (BMI) and lower waist circumference were causally associated with longevity for people older than 80, according to a Mendelian randomization study. European Heart Journal) Disrupted deep sleep, captured.
A new study found patients with a BMI of 32 to 35 have lower odds of responding to the hypoglossal nerve stimulation for OSA compared to patients with a lower BMI.
These real-world, 52-week data demonstrate that deucravacitinib is effective for patients in various age brackets, though BMI has a slight impact on its efficacy.
Women with a higher BMI may have a higher prevalence of cardiovascular risk factors, according to an analysis of the ANCORS-YW study presented during ACC Middle East 2024.
BMI variability has been associated with increased cardiovascular disease risk in individuals with type 2 diabetes, however comparison between clinical studies and real-world observational evidence has been la.
Therefore, this study aims to elucidate the association between CVD and the severity of COPD.MethodsIn this cross-sectional study involving 7,152 individuals with COPD.,
The triglyceride glucose (TyG) index, TyG-body mass index (TyG-BMI), and triglyceride-density lipoprotein cholesterol ratio (TG/HDL-C) are substitute indicators for insulin resistance (IR). This study aimed to.
Patients with low-to-normal body mass index (BMI; < 25.0 kg/m2) were underrepresented in major randomized controlled trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes. The present st.
Preventive Services Task Force (USPSTF) plans to recommend intensive behavioral interventions -- but not pharmacologic therapies -- for kids with a high body mass index (BMI). (MedPage Today) -- The U.S. In its draft recommendation statement.
(MedPage Today) -- Medical experts from around the globe proposed a more nuanced approach to diagnosing obesity that does not rely exclusively on body mass index (BMI) alone. Writing in The Lancet Diabetes & Endocrinology, the global commission.
The TyG-BMI index, which is a reliable indicator of insulin resistance (IR), has been found to have a significant correlation with the occurrence of cardiovascular events. However, there still lacks study on t.
They also often had lower BMI (31.0 While these mortality risks might seem convincing, there are several caveats to keep in mind, including the significant differences in patient characteristics between mechanical and bioprosthetic recipients. Patients receiving bioprosthetic valves tended to be older (65.2 vs 71.8%) or prior PCI (6.7
Each outcome was examined across BMI and BW. Because few patients had a BMI <18.5 kg/m2(n=598), the primary analyses were restricted to those with a BMI ≥18.5 RESULTS:Among 58 464 patients, the median BMI was 28.3 0.88];P<0.001), with a generally consistent effect across BMI (Ptrendacross HRs, 0.48).
People who underwent bariatric surgery had lower BMI and were on fewer medications after five years while maintaining normal blood pressure levels than those who only used antihypertensive medications.
Clinical information, parameters from left ventricular myocardial work and traditional two - dimensional strain echocardiography were collected and analyzed.ResultsAfter LSG, significant reductions in body mass index (BMI), diastolic blood pressure (DBP) and weight were observed.
The interaction between body mass index (BMI) and NT-proBNP with respect to heart failure (HF) risk remains incompletely defined. Hospitalization for heart failure (HHF) was examined across strata of baseline BMI and NT-proBNP. pg/mL lower NT-proBNP per 1 kg/m 2 higher BMI; p<0.001). vs. 0.6%, 1.3% vs. 4.0%, and 8.1%
Maternal height is linked to specific adverse pregnancy events in women with gestational diabetes mellitus, according to a new study. The investigators found shorter women had higher rates of low birth rate and primary c-sections, but taller women had higher rates of abnormal neonatal ponderal index, postpartum hemorrhage, and macrosomia.
The Pearson correlation test was used to detect the association between WWI and BMI. The independent relationship and consistency between WWI and hypertension were assessed through weighted multivariate regression.
Excess weight, as measured by BMI, is typically considered a measure of excess body fat. When someone is classified as being of ‘normal’ weight, that typically means they have a BMI of less than 25. The relationship between excess weight, a high BMI and the risk of severe insulin resistance and diabetes is clear 4.
Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95% CI 1.32 to 1.45) than general adiposity (BMI adjusted for WC; HR 1.22, 95% CI 1.16 Results Over a median follow-up of 13.8 years, there were 10 455 first-ever incident HF events. to 1.33).
Finerenone proved effective regardless of baseline bodyweight , reducing CV death and WHF events across all BMI groups (underweight/normal, rate ratio: 0.80; overweight: 0.91; obesity class I: 0.92; obesity class II-III: 0.67). The drug also significantly improved KCCQ from baseline by an average of 1.62 points at 12 months.
A study of almost 10,000 adults with obesity (BMI >30) who were evaluated for all LE8 factors and followed for over 7 years can give us some insight 1. The Life Essential 8 also include excess weight, but the question is whether those with excess weight who get the remaining seven factors right can significantly decrease their risk.
The primary objective was to understand the association between body mass index (BMI) and heart failure with reduced ejection fraction (HFREF) of ischemic etiology in outpatients, using mortality as a parameter. 56–70), BMI 18.5–24.9 = 35.1%, 24.9 = 35.1%, 25–29.9 = 37.2%, 30–34.9 = 17.8%, 35–39.9 = 7%; BMI <18.5 and BMI 18.5–24.9
Slightly overweight stroke survivors have a lower risk of sustaining disabilities. The Kobe University finding adds another aspect to the obesity paradox but also highlights the importance of considering the population's normal when recommending best practices.
Among patients without diabetes or cardiovascular disease and with a BMI 27 kg/m2, those with coronary artery calcium (CAC) scoring 300 derive the largest benefit from a weight-loss-dose of semaglutide for the prevention of major adverse cardiovascular events (MACE).
What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?
Increases in metabolic risk factors like high blood pressure and BMI have led to a 49.4% increase in global disability-adjusted life years from 2000 to 2021.
Triglyceride-glucose-BMI (TyG-BMI) index is a surrogate marker of insulin resistance and an important predictor of cardiovascular disease. However, the predictive value of TyG-BMI index in the progression of n.
Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). With a BMI 35 kg/m2, lower rule-in thresholds (220 pg/mL) provided good specificity (88% [95% CI, 73%100%]; 93% [95% CI, 81%100%] and 100% in validation cohorts).
All of these patients had a BMI >27. Type 2 diabetes is much more common in those with a BMI in the overweight or obese category but is not uncommon in those who are relatively normal weight. The answer is they were, but just not by conventional BMI standards. But what about those with a relatively normal weight?
Notably, MAG showed superior survival for patients with a BMI less than 40, whereas patients with a BMI of 40 or higher had superior survival with SAG. MAG’s survival advantage over SAG was found in various subgroups, including stable coronary disease, acute coronary syndrome, and acute infarction.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content